Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial
Spain R, et al
Published in Neurology
Methodology
Phase 2 randomized, double-blind, placebo-controlled trial of lipoic acid 1200 mg/day for two years in progressive multiple sclerosis, with change in timed 25-foot walk as the primary outcome plus MRI and disability measures.
Key Findings
Two years of oral lipoic acid 1200 mg/day did not slow decline in timed walking speed or other clinical and MRI measures compared with placebo in progressive multiple sclerosis; gastrointestinal side effects and dropout were common.
Conclusions
Lipoic acid did not slow decline in walking speed or produce clinical effects different from placebo.
Limitations
Moderate sample (n=115) for a two-year progressive MS trial, substantial dropout and adherence problems, and a single dose regimen tested.
Supplements Studied
LA did not slow decline in walking speed or have other clinical effects different from placebo and was associated with newly described adverse events.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Supported by the US Department of Veterans Affairs and the National Multiple Sclerosis Society.
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.